Drug intelligence / Profile preview

Rett-T

Development stage: Phase 2
Lead developer: Holland Bloorview Kids Rehabilitation Hospital
Modality: Small Molecules
Administration: Oral

Overview

Rett-T is an investigational, orally administered fixed-dose antioxidant cocktail being evaluated for **Rett syndrome**. The formulation contains vitamin E, N-acetylcysteine, and alpha-lipoic acid, combining lipid-soluble and thiol-supporting antioxidant activities intended to reduce oxidative stress and support mitochondrial function in the context of MECP2-associated disease biology. Holland Bloorview Kids Rehabilitation Hospital is conducting a Phase 2 placebo-controlled study assessing safety, motor-function outcomes, and biological markers of treatment response in children and adolescents with Rett syndrome.

Other names: Rett-T

Beyond the preview

Go deeper on Rett-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rett-T.

Explore the full profile